Targeted Oncology1h
FDA Pushes Zenocutuzumab Decision Date in NGR1+ NSCLC, PDAC
The FDA has extended its review of zenocutuzumab's in NRG1+ NSCLC and PDAC to February 2025, with efficacy and safety data ...
Targeted Oncology7h
TMI Shows Potential Over Traditional TBI in Hematologic Malignancies
In an interview, Colton Ladbury, MD, discussed new insights from a study and expanded on total marrow irradiation’s potential ...
Targeted Oncology22h
Phase 1 Study of Type II JAK2 Inhibitor in Myelofibrosis Enrolls First Patient
The study is evaluating AJ1-11095, a novel agent for the treatment of myelofibrosis that did not respond to or relapsed ...
Targeted Oncology22h
Patient Selection for Imetelstat Benefits From Considering AEs
Abdulraheem Yacoub, MD, discusses the adverse event profile of imetelstat when treating patients with myelodysplastic ...
Targeted Oncology21h
Navigating Adverse Effects of JAK Inhibitors in Myeloproliferative Neoplasms
Prithviraj Bose, MD, discusses the most critical adverse effects seen with each of the 4 approved JAK inhibitors for the treatment of myeloproliferative neoplasms. Prithviraj Bose, MD, professor in ...